Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 299

Similar articles for PubMed (Select 8875083)

1.

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, André P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwège E.

Diabetes Care. 1996 Sep;19(9):920-6.

PMID:
8875083
2.

Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.

Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA.

Diabetes Metab. 2009 Nov;35(5):385-91. doi: 10.1016/j.diabet.2009.03.005. Epub 2009 Aug 7.

4.

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

Charles MA, Eschwège E, Grandmottet P, Isnard F, Cohen JM, Bensoussan JL, Berche H, Chapiro O, André P, Vague P, Juhan-Vague I, Bard JM, Safar M.

Diabetes Metab Res Rev. 2000 Jan-Feb;16(1):2-7.

PMID:
10707032
5.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.

PMID:
9589227
7.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
10.

Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.

Derosa G, Mereu R, Salvadeo SA, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AF.

Intern Med. 2009;48(5):265-71. Epub 2009 Mar 2.

11.

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S.

Diabetes Care. 2002 Jul;25(7):1123-8. Erratum in: Diabetes Care. 2002 Sep;25(9):1671..

PMID:
12087008
12.
13.
14.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724
15.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
16.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
17.

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.

De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD.

J Intern Med. 2005 Jan;257(1):100-9.

PMID:
15606381
18.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
19.

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

Fanghänel G, Sánchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J.

Diabetes Care. 1996 Nov;19(11):1185-9.

PMID:
8908377
20.

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA.

Diabetes Care. 2000 Aug;23(8):1154-61.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk